"It is vital that the results of this study are implemented and ivabradine is used as part of standard heart failure treatment as soon as possible."
Unlike other treatments, ivabradine lowers the number of heart beats per minute without reducing blood pressure. It has a strong safety record, with fewer trial patients taking it suffering serious side effects than those on other medications.
More than 700,000 people over the age of 45 live with heart failure, which occurs when damage to the heart leaves it too weak to pump blood efficiently round the body. It can lead to serious complications, and around 40 percent of those affected die within a year.
Treating heart failure uses up one to two percent of the total NHS budget each year, with direct medical costs alone reaching £625 million.
Treating a single patient with ivabradine costs around £10 a week.
But American expert Dr John Teerlink, from the University of California in San Francisco, cautioned against rushing into adopting the treatment.
He said there are "many unresolved questions" and additional clinical trials are needed.
"Ivabradine therapy might reduce heart-failure hospitalisations when added to contemporary heart-failure therapies," he wrote in The Lancet.
"However, whether ivabradine can improve outcomes in addition to optimally managed heart failure therapies or its benefits relative to other therapies, especially beta blockers, remains unknown."
Source-AFP